Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH¿AEG¿SEPD¿SEOM¿GETECCU Mar Riveiro-Barciela; Sabela Carballal; Álvaro Díaz-González; Míriam Mañosa; Javier Gallego-Plazas; Joaquín Cubiella; Paula Jiménez-Fonseca; María Varela; Luis Menchén; Bruno Sangro; Ana Fernández-Montes; Francisco Mesonero; Miguel Ángel Rodríguez-Gandía; Fernando Rivera; María-Carlota Londoño;

mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis E Screening in patients with immune impairment and increased transaminases levels) Mar Riveiro-Barciela; Luisa Roade; Joan Martínez-Camprecios; Judit Vidal-González; Basilio Rodríguez-Diez; Manel Perelló; Guillermo Ortí; Virginia Robles-Alonso; Cristina Berastegui; Jordi Navarro; Fernando Martínez-Valle; Itxarone Bilbao; Lluis Castells; Meritxell Ventura-Cots; Jordi Llaneras; Ariadna Rando-Segura; Xavier Forns; Sabela Lens; Martín Prieto; María García-Eliz; Arkaitz Imaz; Francisco Rodríguez-Frías; Maria Buti; Rafael Esteban;

Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy Joan Martínez-Campreciós; Mar Riveiro-Barciela; Raquel Muñoz-Gómez; María-Carlota Londoño; Mercé Roget; Miguel Ángel Serra; Desamparados Escudero-García; Laura Purchades; Manuel Rodríguez; Juan E. Losa-García; María L. Gutiérrez; Isabel Carmona; Javier García-Samaniego; Luís Morano; Ignacio Martín-Granizo; Marta Montero-Alonso; Martín Prieto; Manuel Delgado; Natalia Ramos; María A. Azancot; Francisco Rodríguez-Frías; Maria Buti;